查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591951

高血压药物市场：依治疗方法、分析、类型、分布划分 - 全球预测 2025-2030

Hypertension Drug Market by Therapy (Alpha Blockers, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers), Analysis (Pulmonary Hypertension Drugs, Systemic Hypertension Drugs), Type, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年高血压药物市值为268.8亿美元，预计2024年将达292亿美元，复合年增长率为8.73%，到2030年将达到483.2亿美元。

高血压药物对于控制高血压至关重要，由于与生活方式相关的健康问题越来越多，高血压已成为世界各地的流行病。高血压药物包括多种抗高血压药物，如利尿剂、 β阻断剂、ACE抑制剂和钙通道阻断剂，旨在降低血压并降低心臟病和中风的风险。由于高血压盛行率不断上升、人口老化以及心血管健康意识不断增强，这个市场变得势在必行。其应用涵盖预防性和治疗性治疗，最终用于医院、诊所和居家医疗的持续管理。影响该市场的主要成长要素包括对有效和更安全的药物治疗的需求激增、药物传递技术的进步以及个人化医疗研究投资的增加。开发组合药物以提高疗效和探索数位健康解决方案（例如远端监控）以提高患者的依从性和结果有显着的机会。然而，市场成长受到严格的监管要求、现有药物的潜在副作用以及开发新药的高成本的限制。新颖的、具成本效益的治疗策略可以解决这些挑战。创新领域包括利用人工智慧进行药物发现、利用基因组学进行个人化高血压治疗以及增强药物配方技术。公司应该关注医疗保健基础设施到位并且正在进行意识提升宣传活动的新兴市场。高血压药物市场受到高度监管和竞争，需要不断适应技术进步和人口变化。因此，为了在这个动态的市场环境中取得成功，公司应该投资策略联盟和伙伴关係，并专注于全面的患者解决方案，同时平衡成本、有效性和可及性。

主要市场统计
基准年[2023] 268.8亿美元
预测年份 [2024] 292亿美元
预测年份 [2030] 483.2亿美元
复合年增长率（%） 8.73%

市场动态：揭示快速发展的高血压药物市场的关键市场洞察

供需的动态交互作用正在改变高血压药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 提高对高血压相关併发症的认识
    • 随着人口老化，高血压盛行率增加
    • 高血压药物治疗进展
  • 市场限制因素
    • 偏远地区高血压药物缺乏
  • 市场机会
    • 私人和政府机构不断增加的研发倡议
    • 开发新药日益受到关注
  • 市场挑战
    • 人们越来越担心治疗方法的副作用
    • 替代学名药的增加

波特的五力战略工具驾驭高血压药物市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解高血压药物市场的外部影响

外部宏观环境因素在塑造高血压药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解高血压治疗药物市场的竞争状况

对高血压药物市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 高血压药物市场定位矩阵供应商绩效评估

FPNV 定位矩阵是评估高血压药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘高血压药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，高血压药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高对高血压相关併发症的认识
      • 高血压盛行率增加和人口老化
      • 高血压药物治疗进展
    • 抑制因素
      • 偏远地区买不到高血压药
    • 机会
      • 扩大私人和政府的研发力道
      • 开发新药日益受到关注
    • 任务
      • 人们越来越担心治疗方案的副作用
      • 学名药替代品增加
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 高血压药物市场治疗

  • α阻断剂
  • 血管张力素转化酵素抑制剂
  • 血管收缩素受体阻断剂
  • β阻断剂血管扩张剂
  • 钙离子通道阻断剂
  • 利尿剂
  • 肾素抑制剂

第七章高血压治疗药物市场分析（市场分析）

  • 肺动脉高压治疗药
  • 全身性高血压治疗药

第八章高血压药物市场：依类型

  • 联合治疗
  • 单一疗法

第九章 高血压药物市场经销商

  • 医院药房
  • 网路药房
  • 零售药房

第十章北美与南美高血压药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区高血压药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的高血压药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-43127F727999

The Hypertension Drug Market was valued at USD 26.88 billion in 2023, expected to reach USD 29.20 billion in 2024, and is projected to grow at a CAGR of 8.73%, to USD 48.32 billion by 2030.

Hypertension drugs are crucial in managing high blood pressure, a condition prevalent globally due to increasing lifestyle-induced health issues. The scope of these drugs includes a range of antihypertensives, such as diuretics, beta-blockers, ACE inhibitors, and calcium channel blockers, designed to lower blood pressure and reduce the risk of heart diseases and strokes. This market is essential due to the growing prevalence of hypertension, the aging population, and rising awareness about cardiovascular health. Its applications extend across both preventive and therapeutic treatments, with end-use in hospitals, clinics, and home-based care for continuous management. Key growth factors influencing this market include the surge in demand for effective and safer drug regimens, technological advancements in drug delivery, and increased investment in research for personalized medicine. Notable opportunities exist in the development of combination drugs, which offer enhanced efficacy, and in exploring digital health solutions like remote monitoring to improve patient compliance and outcomes. However, market growth encounters limitations such as stringent regulatory requirements, potential side effects of existing medications, and the high cost of novel drug development. Cost-effective and novel therapeutic strategies could address these challenges. Innovation areas include exploiting artificial intelligence for drug discovery, leveraging genomics for personalized hypertensive medications, and enhancing drug formulation technologies. Businesses should focus on emerging markets with increasing healthcare infrastructure and awareness campaigns. The hypertension drug market, characterized by its regulated and competitive nature, requires ongoing adaptation to technological advancements and demographic shifts. Therefore, companies should invest in strategic collaborations and partnerships that focus on comprehensive patient solutions, balancing cost, efficacy, and accessibility to thrive in this dynamic market environment.

KEY MARKET STATISTICS
Base Year [2023] USD 26.88 billion
Estimated Year [2024] USD 29.20 billion
Forecast Year [2030] USD 48.32 billion
CAGR (%) 8.73%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hypertension Drug Market

The Hypertension Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in awareness related to complications associated with hypertension
    • Increasing prevalence of hypertension coupled with geriatric population
    • Advances in pharmacologic treatment of hypertension
  • Market Restraints
    • Unavailability of hypertension drugs in remote areas
  • Market Opportunities
    • Growing initiatives by private and government organizations for R&D
    • Increasing focus on development of new drugs
  • Market Challenges
    • Increased concern of side-effects of treatment options
    • Rising number of alternate generic drugs

Porter's Five Forces: A Strategic Tool for Navigating the Hypertension Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hypertension Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hypertension Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hypertension Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hypertension Drug Market

A detailed market share analysis in the Hypertension Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hypertension Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hypertension Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hypertension Drug Market

A strategic analysis of the Hypertension Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hypertension Drug Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Hypertension Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy, market is studied across Alpha Blockers, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers, Beta Blockers Vasodilators, Calcium Channel Blockers, Diuretics, and Renin Inhibitors.
  • Based on Analysis, market is studied across Pulmonary Hypertension Drugs and Systemic Hypertension Drugs.
  • Based on Type, market is studied across Combination Therapy and Mono Therapy.
  • Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in awareness related to complications associated with hypertension
      • 5.1.1.2. Increasing prevalence of hypertension coupled with geriatric population
      • 5.1.1.3. Advances in pharmacologic treatment of hypertension
    • 5.1.2. Restraints
      • 5.1.2.1. Unavailability of hypertension drugs in remote areas
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing initiatives by private and government organizations for R&D
      • 5.1.3.2. Increasing focus on development of new drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Increased concern of side-effects of treatment options
      • 5.1.4.2. Rising number of alternate generic drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hypertension Drug Market, by Therapy

  • 6.1. Introduction
  • 6.2. Alpha Blockers
  • 6.3. Angiotensin Converting Enzyme Inhibitor
  • 6.4. Angiotensin Receptor Blockers
  • 6.5. Beta Blockers Vasodilators
  • 6.6. Calcium Channel Blockers
  • 6.7. Diuretics
  • 6.8. Renin Inhibitors

7. Hypertension Drug Market, by Analysis

  • 7.1. Introduction
  • 7.2. Pulmonary Hypertension Drugs
  • 7.3. Systemic Hypertension Drugs

8. Hypertension Drug Market, by Type

  • 8.1. Introduction
  • 8.2. Combination Therapy
  • 8.3. Mono Therapy

9. Hypertension Drug Market, by Distribution

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Hypertension Drug Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hypertension Drug Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hypertension Drug Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bayer AG
  • 3. Boehringer Ingelheim International GmbH
  • 4. Daiichi Sankyo Company, Limited
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. Gilead Sciences, Inc.
  • 7. GlaxoSmithKline PLC
  • 8. Johnson & Johnson Services, Inc.
  • 9. Lupin Limited
  • 10. Merck KGaA
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Sun Pharmaceutical Industries Limited
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. HYPERTENSION DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. HYPERTENSION DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HYPERTENSION DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HYPERTENSION DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY BETA BLOCKERS VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY PULMONARY HYPERTENSION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY SYSTEMIC HYPERTENSION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY MONO THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 193. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, 2023